Incentives for Rare Diseases: the Right Healthcare Priorities?

January 31, 2020

In “Funding the Cure: But For Whom?” segment, Drug Pricing Lab’s Dr. Peter Bach joins Innovation Hub Radio by WGBH to discuss how incentives provided through policies have rewarded innovation for rare drugs and whether these are the right national healthcare priorities today. These rewards for rare diseases have proven to be effective as more resources are directed toward developing gene therapies for orphan indications at the expense of potentially advancing treatment for America’s largest killers, like heart disease or decreasing patient out-of-pocket costs.
View full post and listen online here or tune in via podcast.

Related work:
Dr. Bach presents at the STAT Summit in November 2019:

Our drug policy often prioritizes eliminating rare disease. One researcher asks: Is that the right goal?

View our work describing the pharmaceutical drug reward system and various federal policies’ effects on the rewards and incentives for drug development here.